Literature DB >> 11401117

Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction.

M Hayashi1, T Tsutamoto, A Wada, K Maeda, N Mabuchi, T Tsutsui, H Horie, M Ohnishi, M Kinoshita.   

Abstract

OBJECTIVES: The study evaluates the effect of atrial natriuretic peptide (ANP) compared with nitroglycerin (GTN) on left ventricular (LV) remodeling after first anterior acute myocardial infarction (AMI).
BACKGROUND: Compared with GTN, ANP suppresses the renin-angiotensin-aldosterone system and endothelin-1 (ET-1), which stimulate LV remodeling.
METHODS: Sixty patients with a first anterior AMI were randomly divided into the ANP (n = 30) or GTN (n = 30) groups after direct percutaneous transluminal coronary angioplasty. We evaluated LV ejection fraction (LVEF), end-diastolic volume index (LVEDVI) and end-systolic volume index (LVESVI) at the acute phase and after one month. We also measured neurohumoral factors during study drug infusion.
RESULTS: There was no difference in the baseline characteristics or LVEF (46.9+/-1.0 vs. 46.8+/-1.3%) between the two groups. Although there was no difference in hemodynamics during the infusion periods, the LVEF was significantly improved after one month compared with the baseline value in both groups, but it was improved more in the ANP group than in the GTN group (54.6+/-1.1%, 50.8+/-1.3%, p < 0.05). Left ventricular enlargement was prevented in the ANP group (LVEDVI, 85.8+/-3.1 ml/m2 to 87.3+/-2.7 ml/m2; p = ns, LVESVI, 45.6+/-1.8 ml/m2 to 41.0+/-2.1 ml/m2, p < 0.05) but not in the GTN group (LVEDVI, 86.2+/-4.1 to 100.2+/-3.7, p < 0.01; LVESVI, 46.3+/-2.8 ml/m2 to 51.1+/-3.0 ml/m2, p = ns). During the infusion, ANP suppressed plasma levels of aldosterone, angiotensin II and ET-1 compared with GTN.
CONCLUSIONS: These findings indicate that in patients with a first anterior AMI, an ANP infusion can prevent LV remodeling better than can GTN, and effectively suppresses aldosterone, angiotensin II and ET-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401117     DOI: 10.1016/s0735-1097(01)01233-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.

Authors:  Takahiro Kato; John Muraski; Yan Chen; Yasuyuki Tsujita; Jason Wall; Christopher C Glembotski; Erik Schaefer; Mary Beckerle; Mark A Sussman
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.

Authors:  Paul M McKie; Alessandro Cataliotti; Guido Boerrigter; Horng H Chen; S Jeson Sangaralingham; Fernando L Martin; Tomoko Ichiki; John C Burnett
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

Review 3.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

4.  Relationship between status of plasma atrial natriuretic peptide and heart rate variability in human subjects.

Authors:  Yuji Kasamaki; Yoichi Izumi; Yukio Ozawa; Masakatsu Ohta; Ayako Tano; Ichiro Watanabe; Atsushi Hirayama; Tomohiro Nakayama; Hiroshi Kawamura; Dilxat Himit; Maisumu Mahemuti; Akira Sezai
Journal:  Heart Vessels       Date:  2012-02-28       Impact factor: 2.037

5.  Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate.

Authors:  Robrecht Thoonen; Shewit Giovanni; Suresh Govindan; Dong I Lee; Guang-Rong Wang; Timothy D Calamaras; Eiki Takimoto; David A Kass; Sakthivel Sadayappan; Robert M Blanton
Journal:  Circ Heart Fail       Date:  2015-10-18       Impact factor: 8.790

Review 6.  Natriuretic Peptides and Cardiometabolic Health.

Authors:  Deepak K Gupta; Thomas J Wang
Journal:  Circ J       Date:  2015-06-23       Impact factor: 2.993

7.  Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade.

Authors:  Shuichi Fujita; Naoshi Shimojo; Fumio Terasaki; Kaoru Otsuka; Noriko Hosotani; Yuka Kohda; Takao Tanaka; Tomohiro Nishioka; Toshimichi Yoshida; Michiaki Hiroe; Yasushi Kitaura; Nobukazu Ishizaka; Kyoko Imanaka-Yoshida
Journal:  Heart Vessels       Date:  2013-01-01       Impact factor: 2.037

Review 8.  Novel vasodilators in heart failure.

Authors:  Payman Zamani; Barry H Greenberg
Journal:  Curr Heart Fail Rep       Date:  2013-03

9.  Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study.

Authors:  H H Chen; F L Martin; R J Gibbons; J A Schirger; R S Wright; R M Schears; M M Redfield; R D Simari; A Lerman; A Cataliotti; J C Burnett
Journal:  Heart       Date:  2009-05-15       Impact factor: 5.994

10.  Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.

Authors:  Se Min Ryu; Hark Jei Kim; Kyu Ran Cho; Won-Min Jo
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.